Patents

U.S. patent granted covering use of drug Xanafide for treating multiple types of cancers

Published in Medical Letter on the CDC and FDA, February 26th, 2006

Xanthus Life Sciences, Inc. announced it has been issued U.S. Patent No. 6,989,390 covering the use of Xanthus' cancer drug, Xanafide, a new salt form of amonafide (a topoisomerase 2 inhibitor) for the treatment of a broad range of cancers, including breast, colon, lung, prostate and leukemia.

Xanthus recently initiated a multicenter phase 2 study in patients with secondary acute myeloid leukemia (AML) based on data from a phase 1 study, which showed encouraging activity and an acceptable safety profile. Secondary AML refers to those patients who have developed AML based on an antecedent condition, either myelodysplastic syndrome or prior regimens of chemotherapy or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-02-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry